A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Recruiting in Palo Alto (17 mi)
+50 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Trillium Therapeutics Inc.
No Placebo Group
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
Research Team
PC
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
Inclusion Criteria
You are eligible for Phase 1a Escalation.
You are willing to participate in the Phase 1b dose optimization study, which will involve additional testing and treatments.
You possess normal blood, liver, kidney and clotting functions; as well as access to fresh or stored tumor tissue suitable for immunohistochemical analysis.
See 13 more
Treatment Details
Interventions
- Rituximab (Monoclonal Antibodies)
- TTI-621 (Monoclonal Antibodies)
Participant Groups
16Treatment groups
Experimental Treatment
Group I: T-Cell LymphomaExperimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group II: Small Cell Lung CancerExperimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group III: Rituximab CombinationExperimental Treatment1 Intervention
Combination therapy expansion cohort with PF-07901800 (TTI-621) plus Rituximab for CD20 positive malignancies
Group IV: Peripheral T-Cell Lymphoma (PTCL)Experimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group V: Part 4: Cutaneous T-Cell Lymphoma (CTCL)Experimental Treatment1 Intervention
Monotherapy expansion Part 4 (Dose Optimization) cohort with PF-07901800 (TTI-621)
Group VI: PF-07901800 (TTI-621) Escalation Phase - R/R LymphomaExperimental Treatment1 Intervention
The Escalation Phase will include multiple doses of PF-07901800 (TTI-621)
Group VII: Nivolumab CombinationExperimental Treatment1 Intervention
Combination therapy expansion cohort with PF-07901800 (TTI-621) plus Nivolumab for Hodgkin Lymphoma
Group VIII: Myeloproliferative NeoplasmsExperimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group IX: Myelodysplastic SyndromeExperimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group X: Multiple MyelomaExperimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group XI: Indolent B-Cell LymphomaExperimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group XII: Hodgkin LymphomaExperimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group XIII: Cutaneous T-Cell Lymphoma (CTCL)Experimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group XIV: Chronic Lymphocytic LeukemiaExperimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group XV: Aggressive B-Cell LymphomaExperimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Group XVI: Acute Myeloid LeukemiaExperimental Treatment1 Intervention
Monotherapy expansion cohort with PF-07901800 (TTI-621)
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Laura and Isaac Perlmutter Cancer Center at NYU Langone HealthNew York, NY
NYU Langone Health (Tisch Hospital)New York, NY
Memorial Sloan Kettering Cancer CenterNew York, NY
Oregon Health and Sciences UniversityPortland, OR
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Trillium Therapeutics Inc.
Lead Sponsor
Trials
7
Patients Recruited
620+
Pfizer
Lead Sponsor
Trials
4712
Patients Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13